Pyxis Oncology's MICVO Posts 36% Confirmed ORR and 79% 12-Month OS Probability in 2L+ R/M Head and Neck Cancer
核心洞察
Pyxis Oncology reported updated Phase 1 data for micvotabart pelidotin (MICVO) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (搜索).
In 33 efficacy-evaluable patients dosed at 5.4 mg/kg with a dose cap, MICVO achieved a 36% confirmed objective response rate and 94% disease control rate.
Median progression-free survival reached 6.2 months with a 79% 12-month overall survival probability, and no new safety signals were observed in 35 safety-evaluable patients.
Pyxis Oncology, Inc. (Nasdaq: PYXS) reported positive updated results from its ongoing global Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in patients with second-line and beyond (2L+) recurrent/metastatic head and neck squamous cell carcinoma (搜索) (R/M HNSCC). The data, as of an August 18, 2026 cutoff, showed rapid and deep responses in a heavily pretreated population and support advancement of the antibody-drug conjugate into a pivotal program.
In the 5.4 mg/kg dose-cap population (N=33 efficacy evaluable), MICVO administered intravenously once every three weeks produced a 36% confirmed objective response rate (cORR) and a 94% disease control rate (DCR). Median progression-free survival (mPFS) was 6.2 months (95% CI, 4.8–8.8), and the 12-month overall survival (OS) probability was 79% (95% CI, 58.1–90.3), while median OS had not yet been reached. Seventy-five percent of responders achieved response by the first scan at six weeks, and 83% of responders achieved greater than 50% tumor reduction from baseline per RECIST v1.1.
Clinical activity was observed across key patient subgroups. Among HPV-positive oropharyngeal patients (n=17), cORR was 35% with a median PFS of 6.2 months; in HPV-unrelated disease (n=16), cORR was 38% with a median PFS of 5.9 months. Patients without prior EGFR inhibitor treatment (n=15) had a cORR of 47% and median PFS of 8.8 months, compared with 28% and 5.0 months in those with prior EGFRi exposure (n=18). In the subset with prior novel EGFRi treatment (n=5), cORR was 40% with median PFS of 5.8 months. Prior taxane-treated patients (n=23) showed a cORR of 35% and median PFS of 6.2 months, versus 40% and 4.9 months in those without prior taxane (n=10).
Safety Profile and Dose Capping Strategy
No new safety signals were observed in the 35 safety-evaluable patients. The tolerability profile was consistent with that of other antibody-drug conjugates carrying auristatin payloads and was described as generally manageable. Median treatment duration was 120 days (range, 21–470). All treatment-related adverse events (TRAEs) occurred in 91.4% of patients, with Grade ≥3 TRAEs in 54.3%, non-hematologic Grade ≥3 TRAEs in 42.9%, and serious TRAEs in 14.3%. TRAEs led to treatment discontinuation in 14.3% of patients (one ocular event, one muscle weakness event, and three peripheral neuropathy events) and to dose reduction in 40.0%. There were no treatment-related deaths.
Adverse events of interest included cutaneous events (Grade 1/2 in 48.6%, Grade 3 in 5.7%), peripheral neuropathy (Grade 1/2 in 40.0%, Grade 3 in 17.1%), ocular events (Grade 1/2 in 28.6%, Grade 3 in 5.7%), and pneumonitis (Grade 1/2 in 11.4%, no Grade 3). Peripheral neuropathy generally occurred after patients had received evidence of benefit and after prolonged treatment duration, with median time to onset of 82 days for Grade 1/2 and 166 days for Grade 3 events.
A dose cap was implemented for high body weight patients in December 2025, based on internal pharmacokinetic simulation modeling indicating that MICVO exposures with dose capping and adjusted ideal bodyweight dosing are expected to be comparable. Dose capping was prioritized for its operational simplicity and speed of implementation, and the company reported that it reduced the frequency and severity of adverse events in high body weight patients.
Clinical Rationale and Expert Commentary
MICVO is a first-in-concept antibody-drug conjugate targeting extradomain-B of fibronectin (搜索) (EDB+FN), a non-cellular structural component of the tumor extracellular matrix that is selectively overexpressed in the tumor microenvironment across a wide range of solid tumors and largely absent from normal adult tissues. The agent is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing extracellular matrix density, inhibiting tumor angiogenesis, and mobilizing an anti-tumor immune response. Its non-EGFR targeting mechanism of action positions it to potentially serve patients as the first-line treatment landscape continues to evolve.
"There remains significant need for effective treatment options for patients with recurrent or metastatic head and neck cancer who progress following first-line therapy, particularly as the front-line treatment landscape continues to evolve," said Alan L. Ho, M.D., Ph.D., Chief of the Head and Neck Oncology Service and Attending Medical Oncologist at Memorial Sloan Kettering Cancer Center. "In this heavily pretreated population, these results demonstrated rapid and deep responses, along with progression-free survival and preliminary overall survival results that warrant further evaluation."
Tom Civik, Chief Executive Officer and Chairman of Pyxis Oncology, said the updated data reinforce the company's conviction in MICVO's potential. "We are particularly encouraged by the combination of rapid and deep responses, substantial survival outcomes and a manageable safety profile," he said. "The data also provide important validation of our dose capping strategy, which was intended to maintain clinical activity while mitigating the risk of safety events."
Development Path and Pivotal Trial Design
Pyxis Oncology is advancing MICVO through Project Optimus, the U.S. Food and Drug Administration (搜索) initiative focused on dose optimization and dose selection in oncology drug development. An End of Phase 2 meeting with the FDA to align on dose selection is anticipated in the first quarter of 2027, with updated overall survival data from the monotherapy study expected in the first half of 2027.
The company has aligned with feedback from the FDA and the European Medicines Agency (搜索) on the design of the planned pivotal Phase 3 monotherapy study, Headliner, in patients with second- or third-line R/M HNSCC who have progressed following treatment with both a platinum-based therapy and an anti-PD-1 therapy. The randomized, open-label, two-arm study will enroll approximately 500 patients randomized 1:1 to receive MICVO or investigators' choice of cetuximab, docetaxel, or methotrexate. Co-primary endpoints will be overall response rate and overall survival. Initiation is planned for mid-2027 following alignment with the FDA on dose selection.
MICVO holds Fast Track Designation from the FDA for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)-1 therapy.
Combination Program and Prior Data
Beyond monotherapy, Pyxis Oncology expects to report updated data from an ongoing Phase 1/2 combination dose escalation study of MICVO with Merck (搜索)'s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in first-line R/M HNSCC patients in the fourth quarter of 2026. Preliminary positive results for 1L/2L+ R/M HNSCC were shared in December 2025, and additional data evaluating initial durability and selection of the recommended Phase 3 dose for the 1L combination are expected in the second half of 2027.
The Phase 1 monotherapy study is a multi-part trial. Part 1 was a dose escalation study across multiple doses and tumor types, with initial results shared in November 2024. Part 2 is a dose expansion study in 2L+ R/M HNSCC, comprising two arms: post-platinum and anti-PD-(L)1 patients (Arm 1) and post-EGFR inhibitor and anti-PD-(L)1 patients (Arm 2), each targeting enrollment of approximately 20 patients. Target enrollment in Part 2 was completed in the first quarter of 2026, and preliminary Phase 1 results in 2L+ R/M HNSCC were shared in December 2025.
The updated results compare with a November 3 data cut from the study, which indicated a 46% cORR and 92% DCR for MICVO administered intravenously once every three weeks. Following the release of the updated data, Pyxis shares lost more than 13% in premarket trading on Wednesday.